{"nctId":"NCT01133626","briefTitle":"Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)","startDateStruct":{"date":"2010-06"},"conditions":["Perennial Allergic Rhinitis"],"count":107,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Nasal Aerosol","Drug: Placebo Prednisone Capsules"]},{"label":"BDP HFA 320 Âµg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo Prednisone Capsules","Drug: Beclomethasone dipropionate"]},{"label":"Prednisone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo Nasal Aerosol","Drug: Prednisone capsules"]}],"interventions":[{"name":"Placebo Nasal Aerosol","otherNames":[]},{"name":"Prednisone capsules","otherNames":[]},{"name":"Placebo Prednisone Capsules","otherNames":[]},{"name":"Beclomethasone dipropionate","otherNames":["QNASL(TM)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed Consent\n* Male or female subjects 12-45 years of age\n* Documented history of perennial allergic rhinitis\n* General good health\n* Other criteria apply\n\nExclusion Criteria:\n\n* History of physical findings of nasal pathology (within 60 days prior to Screening Visit 1)\n* Participation in any investigational drug study 30 days preceding Screening Visit 1\n* History of respiratory infection/disorder with 14 days preceding Screening Visit 1\n* Use of any prohibited concomitant medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"45 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment","description":"Geometric mean serum cortisol weighted mean values were calculated at baseline and after 6 weeks (42 days) of treatment. The geometric mean ratio of week 6 / baseline is reported. The primary outcome compares the BDP HFA and Placebo treatment arms. The comparison of active control (Placebo/Prednisone) and Placebo treatment arms is an \"other pre-specified\" outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"1.04"},{"groupId":"OG001","value":"0.95","spread":"1.03"},{"groupId":"OG002","value":"0.31","spread":"1.14"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Epistaxis","Nasal discomfort","Gastroenteritis","Blood oestrogen increased","Dysphonia"]}}}